[admin]

Wuxi NEST Biotechnology Co., Ltd., known by the brand name NEST, built its pharmaceutical packaging and drug delivery business around one industry pain point: the rising incidence of chronic diseases. Its answer is precision dosing and self-administration, designed to reduce clinical workload, minimize needle-stick injuries, and prevent medication waste. Founded in 2018 in Wuxi, Jiangsu, China, the company positions itself as a one-stop provider of pharmaceutical packaging materials and drug delivery technologies, concentrated on injection and inhalation methods, and operates as a high-growth medical technology company. For pharmaceutical buyers evaluating a three-step automatic pen injector custom manufacturer, the practical question is less about a single catalog part than about whether a supplier can co-develop, validate, and mass-produce a device around a specific drug formulation.

What “Three-Step” Refers To in a Pharmaceutical Pen Injector

Within NEST’s 14-product matrix, the term appears in two connected places on the Injection Pen Line:

• Disposable Pen Injector — positioned as a three-step liquid medicine injection device.
• Prefilled Automatic Pen Injector Assembly (Three-Step) — a prefilled automatic assembly listed alongside a two-step variant.

Both sit inside a product line positioned for self-administration in chronic diseases such as diabetes and growth hormone deficiency. That positioning matters commercially: a pharmaceutical customer specifying a three-step device is usually selecting a delivery format that must be validated against a drug, a fill volume, and a patient population, not simply purchased as hardware.

A Fully In-House Chain, from Mold Design to Global Logistics

NEST’s stated differentiated advantage is an end-to-end in-house industry chain: independent mold design and R&D, through automated mass production, through global logistics. Supporting assets include an independent mold center and R&D team that has delivered over 300 precision molds, a 50-person mold maintenance team, and a 76-person specialized quality team. The company also provides Freedom to Operate (FTO) analysis across major global markets including China, the US, the UK, and Europe, which helps pharmaceutical partners mitigate patent risk before a device program advances.

Technical capability rests on a proprietary cross-linked siliconization technology developed to maintain stable gliding performance in syringes and cartridges. Quality control includes 100% multi-angle CCD camera inspection and moist heat sterilization capabilities (SAL 10⁻⁶).

Manufacturing Footprint and Cleanroom Capacity

Physical scale is a meaningful filter when qualifying a custom pen injector supplier:

• 10,600 m² of Class 100,000 cleanrooms
• 3,600 m² of Class 10,000 cleanrooms
• A 2,300 m² pen injector workshop

The TSA Disposable Pen Injector, an internal-rotation type pen with no outward-extending components during dose adjustment, is manufactured in a 100,000-class cleanroom. Geographically, the company covers China, the United States, the Netherlands, the United Arab Emirates, Japan, and Turkey: headquarters and R&D in Wuxi; subsidiaries and warehouses in Woodbridge, NJ and Phoenix, AZ; a subsidiary and warehouse in Hendrik-Ido-Ambacht, Netherlands; a subsidiary and warehouse in Sharjah, UAE; a subsidiary in Yokohama, Japan; and a subsidiary in Istanbul, Turkey.

Certifications and Regulatory Reach

Between 2023 and 2025, NEST secured multiple international certifications and licenses for its pen injector and syringe product lines. The current portfolio includes ISO 9001, ISO 13485, ISO 11137, ISO 15378, IATF 16949, CE MDR Certification, and MDSAP five-country certification (USA, Canada, Australia, Japan, Brazil). US filings include FDA 510(k) (K240961, K240774) and US DMF (No. 40744, No. 42439, No. 40922); Canadian registration includes Medical Device License No. 113733 and No. 112619; Chinese registration includes a China Class II Medical Device Certificate. Third-party certification from TÜV SÜD covers ISO 9001/13485/11137.

Customization Scope: Dosage, Appearance, and Data Validation

For the Disposable Pen Injector, the target scenario pain points are the high cost of reusable devices and the risk of cross-contamination. Differentiated value is expressed in two directions: customization of appearance and dosage across 36/37/50/60/74/75/80 units, and accuracy supported by professional data validation support. Key features include visual and auditory feedback and an injection start force of ≤10 N (up to 60 IU).

Adjacent options broaden the custom brief:

• Reusable Pen Injector — a long-term injection device with replaceable cartridges, offering 3,000+ cycles of lifecycle durability and support for both IU and mg scaling.
• Prefilled Automatic Pen Injector Assembly (Two-Step) — a disposable, spring-driven auto-injection device addressing needle anxiety and manual force limitations, with a hidden needle and an automatic locking shield post-injection.
• Disposable Fixed-dose Pen Injector and Self-locking Pen Injector (100 IU) extend the range further.

Platform Compatibility and Primary Packaging

Compatibility is a stated design principle: NEST devices are compatible with major international prefilled syringe (PFS) and automatic pen injector components. Primary packaging includes RTU Cartridges in borosilicate glass with proprietary cross-linked siliconization, available in 1.5mL, 2.0mL, and 3.0mL, and the COP/COC Prefillable Vial (AccureVial®), positioned as a high-quality alternative to borosilicate glass for sensitive biologics, with low protein adsorption, shatter-resistant COP material, and temperature tolerance of -196°C to 121°C. A COP/COC Prefilled Syringe Assembly, a Prefilled Nasal Spray Assembly, and a Filling and Stoppering Machine complete the offering.

Service scope is equally relevant to custom programs: one-stop solutions spanning R&D, production, pre-sterilization, and customized assembly, plus pre-sales customization, technical validation, automated assembly line planning, and global logistics, with integrated warehousing in the US, Europe, and Asia to shorten lead times. Full lifecycle validation and batch traceability are maintained via batch numbers and retained samples, and the company reports compliance with RoHS and REACH regulations.

Case Evidence: Intranasal Vaccine Delivery

One documented case involves a Lyophilized Live Attenuated Influenza Vaccine. The business scenario is intranasal vaccination; the solution deployed was the Disposable Intranasal Atomization Device, and the quantified result was successful stimulation of a triple immune response (Mucosal, Humoral, Cellular). Notably, the company obtained registration for the Disposable Intranasal Atomization Device in 2019, one year after its 2018 entry into pharmaceutical packaging materials — evidence of a delivery-route portfolio that spans both injection and inhalation.

Buyers, Pricing, and Delivery Model

Industries covered are biopharmaceuticals, medical aesthetics, and life sciences, with customer types including pharmaceutical companies (insulin, GLP-1, and FSH manufacturers), research institutions, and hospitals. Pricing follows a custom enterprise pricing approach based on volume and customization requirements. Deployment covers hardware (medical devices) and related equipment sales, backed by full product lifecycle technical support and validation assistance. Ecosystem development runs through partnerships with global pharmaceutical companies for final device assembly and drug-device combination validation.

Market recognition material identifies the company as a provider of the first moist heat sterilized cartridges in China. Taken together — the in-house mold-to-logistics chain, the cleanroom capacity, the 2023–2025 regulatory filings, and the customization range of 36 to 80 units — Wuxi NEST Biotechnology Co., Ltd. presents itself as a specialized partner for pharmaceutical teams seeking a three-step automatic pen injector custom manufacturing program rather than a standard catalog device.

https://www.cell-nestbio.com/
NEST Biotechnology Co., Ltd.

[Author]

Posts